Going from social neuroscience to schizophrenia clinical trials

Schizophrenia Bulletin

Volumn 39, Issue 6, 2013, Pages 1189-1191

  Green, Michael F ^a,b   Penn, David L ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Clinical trials; Schizophrenia; Social cognition; Social neuroscience

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); ELECTROPHYSIOLOGY; EMOTION; EMPATHY; EXTERNAL VALIDITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL STATUS; HUMAN; MENTAL DISEASE; NEUROSCIENCE; PRIORITY JOURNAL; PSYCHOMETRY; RECOGNITION; SCHIZOPHRENIA; SOCIAL COGNITION; STRUCTURAL EQUATION MODELING; TEST RETEST RELIABILITY;

CLINICAL TRIALS; SCHIZOPHRENIA; SOCIAL COGNITION; SOCIAL NEUROSCIENCE;

CLINICAL TRIALS AS TOPIC; HUMANS; NEUROSCIENCES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 84886056167     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt128     Document Type: Article

References (14)

1. Horan WP, Kern RS, Tripp C, et al. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res. 2011;45:1113-1122.
2. Wölwer W, Frommann N, Halfmann S, Piaszek A, Streit M, Gaebel W. Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res. 2005;80:295-303. (Pubitemid 41713655)
3. Roberts DL, Penn DL. Social cognition and interaction training (SCIT) for outpatients with schizophrenia: a preliminary study. Psychiatry Res. 2009;166:141-147.
4. Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011;132:50-53.
5. Davis MC, Lee J, Horan WP, et al. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res. 2013;147:393-397.
6. Fischer-Shofty M, Brüne M, Ebert A, Shefet D, Levkovitz Y, Shamay-Tsoory SG. Improving social perception in schizophrenia: the role of oxytocin. Schizophr Res. 2013;146: 357-362.
7. Carter CS, Barch DM. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull. 2007;33:1131-1137. (Pubitemid 47347921)
8. Ochsner KN. The social-emotional processing stream: five core constructs and their translational potential. Biol Psychiatry. 2008;64:48-61. (Pubitemid 351783246)
9. Gold JM, Barch DM, Carter CS, et al. Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. Schizophr Bull. 2012;38:144-152.
10. Pinkham AE, Penn DL, Green MF, Buck B, Healey K, Harvey PD. The Social Cognition Psychometric Evaluation (SCOPE) study: results of the expert survey and RAND panel. Schizophr Bull. In press.
11. Green MF, Lee J, Ochsner KN. Adapting social neuroscience measures for schizophrenia clinical trials, Part 1: ferrying paradigms across perilous waters. Schizophr Bull. This issue.
12. Kern RS, Penn DL, Lee J, et al. Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling in the depths of psychometric properties. Schizophr Bull. This issue.
13. Olbert CM, Penn DL, Kern RS, et al. Adapting social neuroscience measures for schizophrenia clinical trials, Part 3: fathoming external validity. Schizophr Bull. This issue.
14. Green MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry 2012;69:1216-1224.